+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oral Asthma Medications Market by Drug Class (Leukotriene Inhibitors, Mast Cell Stabilizers, Theophyllines), Distribution Channel (Drug Stores, Hospital Pharmacy, Online Pharmacy), Formulation, Prescription Status, Age Group - Global Forecast 2025-2030- Product Image
Oral Asthma Medications Market by Drug Class (Leukotriene Inhibitors, Mast Cell Stabilizers, Theophyllines), Distribution Channel (Drug Stores, Hospital Pharmacy, Online Pharmacy), Formulation, Prescription Status, Age Group - Global Forecast 2025-2030- Product Image
New

Oral Asthma Medications Market by Drug Class (Leukotriene Inhibitors, Mast Cell Stabilizers, Theophyllines), Distribution Channel (Drug Stores, Hospital Pharmacy, Online Pharmacy), Formulation, Prescription Status, Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6147889
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Comprehensive Examination of Oral Asthma Therapeutics and Their Integration into Modern Respiratory Care Pathways Across Heterogeneous Patient Populations

The oral asthma medication arena has evolved dramatically, blending traditional remedies with novel therapeutic classes and integrated care philosophies. As clinicians and healthcare systems strive to balance efficacy with safety and patient adherence, the landscape of available options now spans multiple drug categories that address diverse pathophysiological mechanisms. This complexity underscores the need to understand how distinct therapies fit into comprehensive management pathways.

Shifts in clinical guidelines, patient expectations, and technology-enabled prescribing models have introduced new dynamics into product development and commercialization efforts. The journey from early mast cell stabilization approaches to modern leukotriene receptor antagonists illustrates how scientific advances can translate into meaningful patient outcomes. Meanwhile, the role of generic theophylline formulations continues to be redefined by sustained‐release innovations and safety monitoring practices.

Against this backdrop, stakeholders require a nuanced introduction to contextualize the interplay between therapeutic innovation, regulatory changes, and evolving care delivery models. This section establishes the foundation for exploring transformative shifts, external pressures, and strategic imperatives that will shape the future of oral asthma medications.

Examining Transformative Shifts in the Oral Asthma Medication Landscape Driven by Technological Innovation Market Dynamics and Policy Evolution Strategies

Innovation, policy reform, and shifting patient needs have converged to reshape the oral asthma medication environment. Technological breakthroughs in drug delivery and molecular targeting have expanded the reach of established classes such as leukotriene inhibitors and theophyllines, while reinforcing the enduring relevance of mast cell stabilizers in specific patient segments. Interoperability of digital health platforms now enables remote monitoring of treatment efficacy, catalyzing a more proactive approach to managing exacerbations.

Concurrently, healthcare payers and regulatory bodies are reexamining pricing frameworks and reimbursement criteria, prompting manufacturers to adopt more flexible commercial models. These adaptations include value-based contracting and patient support services designed to enhance adherence and outcomes. The combined effect of these forces has heightened competition among incumbent leaders and emerging entrants alike.

Today’s market dynamic demands that decision-makers embrace agility and foresight. By charting the evolution from first-generation stabilizers to today’s precision-oriented leukotriene antagonists, this analysis highlights how strategic pivots in research and stakeholder engagement will continue to drive progress in oral asthma care.

Analyzing the Cumulative Impact of United States Tariff Adjustments on Oral Asthma Medication Supply Chains Pricing and Stakeholder Alignment in Year Ahead

The imposition of new tariff structures in the United States, effective in the upcoming year, will have far-reaching consequences across the oral asthma medication supply chain. Raw material sourcing, primarily for active pharmaceutical ingredients derived from global suppliers, will face altered cost inputs. Manufacturers and distributors must adapt their procurement and inventory strategies in response to these changes, as upward pricing pressures could influence contract negotiations with both public and private payers.

As import costs rise, smaller generic producers may encounter constraints in maintaining competitive pricing, potentially affecting product availability in community pharmacies. At the same time, larger multinational corporations with integrated supply networks may leverage scale to absorb certain expense shifts, maintaining continuity of supply for key formulations. The cumulative impact of these adjustments will ripple through downstream channels, from hospital pharmacies to online platforms, altering the cost structure for healthcare providers and patients alike.

To mitigate potential disruptions, stakeholders should explore strategic sourcing partnerships, alternative manufacturing locations, and forward‐looking hedging mechanisms. Understanding the nuances of these tariff adjustments will be critical for sustaining operational resilience and ensuring consistent patient access to oral asthma therapies.

Deriving Actionable Insights from Therapeutic Class Distribution Channel Formulation Prescription Status and Age Group Segmentation in Oral Asthma Treatments

Segmentation based on drug class reveals distinct trends across widely used leukotriene inhibitors including montelukast, zafirlukast, and zileuton, as well as sustained interest in mast cell stabilizers such as cromolyn sodium and nedocromil, alongside emerging niche applications for nedocromil. Theophylline formulations, divided into immediate-release and sustained-release variants, continue to address specific patient needs where cost constraints or historical prescribing habits persist.

Distribution channel analysis underscores the divergent roles of drug stores and hospital pharmacies in serving acute and chronic care settings, while online pharmacy, retail pharmacy, and emerging digital dispensaries broaden patient access and support adherence through home delivery services. These channels reflect an ongoing shift toward patient-centric dispensing models that emphasize convenience and real-time monitoring.

Formulation preferences vary explicitly between capsules, sachets, syrups, and tablets, highlighting the importance of age-appropriate dosing and swallow-ability considerations for pediatric and geriatric populations. Prescription status segmentation delineates over-the-counter options that empower self-management alongside prescription-only therapies reserved for clinician oversight. Age group distinctions among adults, geriatric patients, and pediatric cohorts further inform tailored communication strategies and safety monitoring protocols.

By weaving together these segmentation lenses, stakeholders can pinpoint high-value opportunities and anticipate patient journey nuances that drive adoption, adherence, and long-term outcomes.

Uncovering Regional Dynamics Shaping Oral Asthma Medication Adoption and Accessibility in Americas Europe Middle East Africa and Asia Pacific Markets

Regional dynamics exert a profound influence on the adoption, accessibility, and commercialization of oral asthma medications. In the Americas, fragmented reimbursement systems and a strong emphasis on generics interplay with patient assistance programs and direct-to-consumer education campaigns to shape prescribing patterns. Emerging telehealth initiatives are also enabling broader outreach across rural and underserved communities, altering the traditional pharmacy network landscape.

Within Europe, the Middle East, and Africa, heterogeneous regulatory frameworks and varying healthcare infrastructure capacities drive disparate uptake rates. Centralized approval processes in some European markets contrast with decentralized systems in others, prompting manufacturers to deploy differentiated market entry strategies. In many Middle Eastern and African markets, affordability constraints and infrastructural gaps underscore the need for partnerships that bolster supply chain resilience and local capacity building.

The Asia-Pacific region encapsulates a spectrum of mature, highly regulated environments alongside rapidly expanding emerging markets. Government initiatives promoting essential medicine lists and subsidized access programs are affecting pricing and distribution models, while private channel growth, particularly in urban centers, is fueling demand for innovative dosage forms. Stakeholders must navigate a tapestry of policy initiatives, demographic factors, and competitive landscapes to maximize regional impact.

Highlighting Competitive Strategies and Innovation Trajectories of Leading Pharmaceutical Players in the Oral Asthma Medication Ecosystem

Leading pharmaceutical players continue to refine their portfolios, balancing brand‐name innovation with strategic generic launches. Certain incumbents have prioritized expansion of oral leukotriene antagonist pipelines, seeking to deliver enhanced safety profiles and once-daily dosing to improve patient adherence. Others have invested in novel co-formulations, pairing anti‐inflammatory agents with bronchodilators to broaden therapeutic appeal.

In the generic sector, several key manufacturers have pursued cost-optimization of theophylline production, leveraging advanced continuous manufacturing platforms to reduce cycle times and improve quality control. This approach has enabled them to maintain competitive positioning in price-sensitive markets while addressing heightened regulatory scrutiny and risk management expectations.

Strategic alliances and licensing agreements have also marked recent activity, with mid-sized firms collaborating with biotech innovators to gain early access to next-generation stabilizing agents. These partnerships not only accelerate clinical development but also facilitate entry into niche segments such as pediatric formulations and digital adherence solutions. As a result, the competitive tapestry of the oral asthma ecosystem continues to evolve, driven by a blend of targeted R&D, operational excellence, and collaborative business models.

Formulating Actionable Recommendations for Industry Leaders to Enhance Market Position Leverage Patient Centricity and Streamline Operational Excellence

Industry leaders should adopt a multifaceted approach that aligns patient outcomes with commercial objectives through a robust portfolio management strategy. Investing in adherence support platforms that integrate mobile health applications can drive improved compliance, reduce exacerbations, and strengthen payer negotiations. Concurrently, leveraging real-world evidence to demonstrate long-term value and safety will enhance formulary placement and foster stakeholder trust.

It is imperative to revisit manufacturing footprints in light of evolving tariff landscapes and supply chain vulnerabilities. Establishing dual‐source agreements and localizing critical production nodes can safeguard against sudden cost escalations and distribution bottlenecks. Moreover, forging strategic partnerships with contract manufacturing organizations across key regions will enable rapid scaling and responsive market entry.

Finally, cultivating deeper engagement with regulatory bodies and patient advocacy groups will support the co-creation of next-generation therapies and address unmet needs. Engaging early with health authorities around adaptive licensing pathways and value-based contracting models can accelerate time to market and secure premium positioning for innovative formulations.

Explaining Robust Mixed Method Research Approach and Data Collection Framework with Analytical Techniques Ensuring Rigor and Reliability

The research methodology underpinning this analysis employs a blended approach that integrates primary engagements with industry experts and structured secondary research across peer-reviewed journals, regulatory databases, and public filings. Insights from key opinion leaders, including pulmonologists and pharmacy directors, provided qualitative depth, while quantitative validation was achieved through systematic data triangulation.

Background review encompassed comprehensive assessment of clinical trial registries, patent landscapes, and government policy documents to map innovation trajectories and regulatory trends. This was complemented by a detailed examination of supply chain structures, pricing frameworks, and distribution networks derived from publicly available sources, industry white papers, and trade publications.

Analytical techniques included thematic analysis of interview transcripts to uncover unmet needs and barrier points, as well as comparative benchmarking of competitor strategies. Findings were further refined through cross-verification with market intelligence databases and scenario planning exercises. Together, these methods ensure that the report delivers reliable, evidence-based insights capable of guiding strategic decision making in the dynamic oral asthma medication landscape.

Summarizing Key Findings and Future Outlook for Oral Asthma Treatments Emphasizing Strategic Imperatives for Stakeholders Across the Ecosystem

This report brings into focus the critical drivers, emerging trends, and strategic imperatives impacting oral asthma therapies across therapeutic classes, distribution channels, and patient segments. The convergence of technological innovation, policy shifts, and evolving patient expectations has created a dynamic environment that demands agile responses from manufacturers and stakeholders alike.

Key takeaways highlight the necessity of portfolio diversification to balance legacy and novel therapies, continued investment in digital adherence tools, and proactive supply chain risk management in the face of tariff adjustments. Regional nuances further underscore the importance of market-specific strategies that address regulatory complexity and healthcare infrastructure disparities.

Looking ahead, the interplay between real-world evidence generation, value-based contracting, and patient-centric care models will define competitive advantage. Stakeholders who harness these levers effectively will be best positioned to deliver meaningful improvements in patient outcomes while capturing sustainable growth opportunities.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Leukotriene Inhibitors
      • Montelukast
      • Zafirlukast
      • Zileuton
    • Mast Cell Stabilizers
      • Cromolyn Sodium
      • Nedocromil
    • Theophyllines
      • Immediate Release
      • Sustained Release
  • Distribution Channel
    • Drug Stores
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Formulation
    • Capsules
    • Sachet
    • Syrup
    • Tablets
  • Prescription Status
    • Otc
    • Prescription
  • Age Group
    • Adult
    • Geriatric
    • Pediatric
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Novartis AG
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of oral small molecule DP2 receptor antagonists in severe asthma management
5.2. Development of patient-friendly orally disintegrating montelukast tablets to boost pediatric adherence
5.3. Clinical advancement of oral TSLP inhibitors as targeted therapies for eosinophilic asthma phenotypes
5.4. Integration of pharmacogenomic testing to personalize oral asthma medication regimens for improved outcomes
5.5. Expansion of combination oral leukotriene receptor antagonists with antihistamines for dual symptom control
5.6. Growing focus on oral probiotic adjunct therapies to modulate gut-lung axis in chronic asthma patients
5.7. Progress in oral JAK inhibitors targeting airway inflammation for corticosteroid-sparing asthma care
5.8. Increasing off-label use and clinical trials of repurposed oral antihypertensive agents for asthma control
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Oral Asthma Medications Market, by Drug Class
8.1. Introduction
8.2. Leukotriene Inhibitors
8.2.1. Montelukast
8.2.2. Zafirlukast
8.2.3. Zileuton
8.3. Mast Cell Stabilizers
8.3.1. Cromolyn Sodium
8.3.2. Nedocromil
8.4. Theophyllines
8.4.1. Immediate Release
8.4.2. Sustained Release
9. Oral Asthma Medications Market, by Distribution Channel
9.1. Introduction
9.2. Drug Stores
9.3. Hospital Pharmacy
9.4. Online Pharmacy
9.5. Retail Pharmacy
10. Oral Asthma Medications Market, by Formulation
10.1. Introduction
10.2. Capsules
10.3. Sachet
10.4. Syrup
10.5. Tablets
11. Oral Asthma Medications Market, by Prescription Status
11.1. Introduction
11.2. Otc
11.3. Prescription
12. Oral Asthma Medications Market, by Age Group
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Pediatric
13. Americas Oral Asthma Medications Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Oral Asthma Medications Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Oral Asthma Medications Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. GlaxoSmithKline plc
16.3.2. AstraZeneca plc
16.3.3. Novartis AG
16.3.4. Sanofi S.A.
16.3.5. Merck & Co., Inc.
16.3.6. Boehringer Ingelheim International GmbH
16.3.7. Teva Pharmaceutical Industries Ltd.
16.3.8. Cipla Limited
16.3.9. Sun Pharmaceutical Industries Ltd.
16.3.10. Viatris Inc.
17. Research AI18. Research Statistics19. Research Contacts20. Research Articles21. Appendix
List of Figures
FIGURE 1. ORAL ASTHMA MEDICATIONS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ORAL ASTHMA MEDICATIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ORAL ASTHMA MEDICATIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ORAL ASTHMA MEDICATIONS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ORAL ASTHMA MEDICATIONS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ORAL ASTHMA MEDICATIONS MARKET: RESEARCHAI
FIGURE 26. ORAL ASTHMA MEDICATIONS MARKET: RESEARCHSTATISTICS
FIGURE 27. ORAL ASTHMA MEDICATIONS MARKET: RESEARCHCONTACTS
FIGURE 28. ORAL ASTHMA MEDICATIONS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ORAL ASTHMA MEDICATIONS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MONTELUKAST, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MONTELUKAST, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY ZAFIRLUKAST, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY ZAFIRLUKAST, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY ZILEUTON, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY ZILEUTON, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY CROMOLYN SODIUM, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY CROMOLYN SODIUM, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY NEDOCROMIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY NEDOCROMIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG STORES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY SACHET, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY SACHET, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY SYRUP, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY SYRUP, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY OTC, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY OTC, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS ORAL ASTHMA MEDICATIONS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 107. CANADA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 108. CANADA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 109. CANADA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 110. CANADA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 111. CANADA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2024 (USD MILLION)
TABLE 112. CANADA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2025-2030 (USD MILLION)
TABLE 113. CANADA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2018-2024 (USD MILLION)
TABLE 114. CANADA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2025-2030 (USD MILLION)
TABLE 115. CANADA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. CANADA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. CANADA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 118. CANADA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 119. CANADA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
TABLE 120. CANADA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2030 (USD MILLION)
TABLE 121. CANADA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 122. CANADA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 123. MEXICO ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 124. MEXICO ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 125. MEXICO ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 126. MEXICO ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 127. MEXICO ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2024 (USD MILLION)
TABLE 128. MEXICO ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2025-2030 (USD MILLION)
TABLE 129. MEXICO ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2018-2024 (USD MILLION)
TABLE 130. MEXICO ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2025-2030 (USD MILLION)
TABLE 131. MEXICO ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. MEXICO ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. MEXICO ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 134. MEXICO ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 135. MEXICO ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
TABLE 136. MEXICO ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2030 (USD MILLION)
TABLE 137. MEXICO ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 138. MEXICO ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 205. GERMANY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 206. GERMANY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 207. GERMANY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 208. GERMANY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 209. GERMANY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2024 (USD MILLION)
TABLE 210. GERMANY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2025-2030 (USD MILLION)
TABLE 211. GERMANY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2018-2024 (USD MILLION)
TABLE 212. GERMANY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2025-2030 (USD MILLION)
TABLE 213. GERMANY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. GERMANY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. GERMANY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 216. GERMANY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 217. GERMANY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
TABLE 218. GERMANY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2030 (USD MILLION)
TABLE 219. GERMANY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 220. GERMANY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 221. FRANCE ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 222. FRANCE ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 223. FRANCE ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. FRANCE ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. FRANCE ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2024 (USD MILLION)
TABLE 226. FRANCE ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2025-2030 (USD MILLION)
TABLE 227. FRANCE ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2018-2024 (USD MILLION)
TABLE 228. FRANCE ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2025-2030 (USD MILLION)
TABLE 229. FRANCE ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. FRANCE ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. FRANCE ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 232. FRANCE ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 233. FRANCE ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
TABLE 234. FRANCE ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2030 (USD MILLION)
TABLE 235. FRANCE ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 236. FRANCE ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2030 (USD MILLION)
TABLE 251. RUSSIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 252. RUSSIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 253. ITALY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 254. ITALY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 255. ITALY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 256. ITALY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 257. ITALY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2024 (USD MILLION)
TABLE 258. ITALY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2025-2030 (USD MILLION)
TABLE 259. ITALY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2018-2024 (USD MILLION)
TABLE 260. ITALY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2025-2030 (USD MILLION)
TABLE 261. ITALY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. ITALY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. ITALY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 264. ITALY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 265. ITALY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
TABLE 266. ITALY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2030 (USD MILLION)
TABLE 267. ITALY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 268. ITALY ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 269. SPAIN ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 270. SPAIN ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 271. SPAIN ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 272. SPAIN ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 273. SPAIN ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2024 (USD MILLION)
TABLE 274. SPAIN ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2025-2030 (USD MILLION)
TABLE 275. SPAIN ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2018-2024 (USD MILLION)
TABLE 276. SPAIN ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2025-2030 (USD MILLION)
TABLE 277. SPAIN ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. SPAIN ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. SPAIN ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 280. SPAIN ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 281. SPAIN ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
TABLE 282. SPAIN ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2030 (USD MILLION)
TABLE 283. SPAIN ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 284. SPAIN ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY LEUKOTRIENE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY MAST CELL STABILIZERS, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY THEOPHYLLINES, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
TABLE 314. SAUDI ARABIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 316. SAUDI ARABIA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 318. SOUTH AFRICA ORAL ASTHMA MEDICATIONS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA ORAL ASTHMA MEDICA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Oral Asthma Medications Market report include:
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Novartis AG
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.

Related Topics

Related Reports

Asthma Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030 - Product Image

Asthma Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • Report
  • 120 Pages
  • Global
From
Asthma Therapeutics Market by Product Type (Biologics, Inhalers, Nebulizers), Drug Class (Beta Agonists, Combination Therapies, Inhaled Corticosteroids), Distribution Channel, Route Of Administration, End User - Global Forecast 2025-2030 - Product Image

Asthma Therapeutics Market by Product Type (Biologics, Inhalers, Nebulizers), Drug Class (Beta Agonists, Combination Therapies, Inhaled Corticosteroids), Distribution Channel, Route Of Administration, End User - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Asthma Treatment - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Asthma Treatment - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
United States Asthma Treatment Market, By Region, Competition, Forecast & Opportunities, 2020-2030F - Product Image

United States Asthma Treatment Market, By Region, Competition, Forecast & Opportunities, 2020-2030F

  • Report
  • 82 Pages
  • United States
From
Asthma Treatment Market Report and Forecast 2023-2031 - Product Image

Asthma Treatment Market Report and Forecast 2023-2031

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.